Modeling Duchenne Muscular Dystrophy Cardiomyopathy with Patients’ Induced Pluripotent Stem-Cell-Derived Cardiomyocytes
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24108657 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Binyamin Eisen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cardiac Research Laboratory, Department of Physiology, Biophysics and Systems Biology, Rappaport Faculty of Medicine and Research Institute, Technion…. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Induced Pluripotent Stem Cells, Cardiomyopathies. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 212 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Israel Science Foundation (ISF), Niedersachsen Foundation, US–Israel Binational Foundation (BSF).
Abstract (Originalsprache)
Duchenne muscular dystrophy (DMD) is an X-linked progressive muscle degenerative disease caused by mutations in the dystrophin gene, resulting in death by the end of the third decade of life at the latest. A key aspect of the DMD clinical phenotype is dilated cardiomyopathy, affecting virtually all patients by the end of the second decade of life. Furthermore, despite respiratory complications still being the leading cause of death, with advancements in medical care in recent years, cardiac involvement has become an increasing cause of mortality. Over the years, extensive research has been conducted using different DMD animal models, including the mdx mouse. While these models present certain important similarities to human DMD patients, they also have some differences which pose a challenge to researchers. The development of somatic cell reprograming technology has enabled generation of human induced pluripotent stem cells (hiPSCs) which can be differentiated into different cell types. This technology provides a potentially endless pool of human cells for research. Furthermore, hiPSCs can be generated from patients, thus providing patient-specific cells and enabling research tailored to different mutations. DMD cardiac involvement has been shown in animal models to include changes in gene expression of different proteins, abnormal cellular Ca2+ handling, and other aberrations. To gain a better understanding of the disease mechanisms, it is imperative to validate these findings in human cells. Furthermore, with the recent advancements in gene-editing technology, hiPSCs provide a valuable platform for research and development of new therapies including the possibility of regenerative medicine. In this article, we review the DMD cardiac-related research performed so far using human hiPSCs-derived cardiomyocytes (hiPSC-CMs) carrying DMD mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiac Research Laboratory, Department of Physiology, Biophysics and Systems Biology, Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
ORCID-Profile: Binyamin Eisen, Ofer Binah
Förderung
- Israel Science Foundation (ISF)
- Niedersachsen Foundation
- US–Israel Binational Foundation (BSF)
- Association Duchenne Israel
- Duchenne Parent Project Netherlands (DPP NL)
Zitieren
APA
Eisen, B., & Binah, O. (2023). Modeling Duchenne Muscular Dystrophy Cardiomyopathy with Patients’ Induced Pluripotent Stem-Cell-Derived Cardiomyocytes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24108657
Vancouver
Eisen B, Binah O. Modeling Duchenne Muscular Dystrophy Cardiomyopathy with Patients’ Induced Pluripotent Stem-Cell-Derived Cardiomyocytes. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24108657
BibTeX
@article{Eisen2023,
author = {Eisen, Binyamin and Binah, Ofer},
title = {Modeling Duchenne Muscular Dystrophy Cardiomyopathy with Patients’ Induced Pluripotent Stem-Cell-Derived Cardiomyocytes},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24108657}
}
EUVIMED